849875
Last Update Posted: 2017-07-12
Recruiting has ended
All Genders accepted | 18 Years + |
48 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when given in combination with dacarbazine and evaluate the safety of this combination.
This Protocol Posting has been updated following amendment 3, dated 16 October 2009. The sections impacted are :
- Enrollment, number of subjects
- Outcome measures
- Exclusion criteria
Eligibility
Relevant conditions:
Melanoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov